Cargando…
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists
[Image: see text] Purine (N)-methanocarba-5′-N-alkyluronamidoriboside A(3) adenosine receptor (A(3)AR) agonists lacking an exocyclic amine resulted from an unexpected reaction during a Sonogashira coupling and subsequent aminolysis. Because the initial C6-Me and C6-styryl derivatives had unexpectedl...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2016
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970510/ https://www.ncbi.nlm.nih.gov/pubmed/26890707 http://dx.doi.org/10.1021/acs.jmedchem.5b01998 |
_version_ | 1782445985425784832 |
---|---|
author | Tosh, Dilip K. Ciancetta, Antonella Warnick, Eugene O’Connor, Robert Chen, Zhoumou Gizewski, Elizabeth Crane, Steven Gao, Zhan-Guo Auchampach, John A. Salvemini, Daniela Jacobson, Kenneth A. |
author_facet | Tosh, Dilip K. Ciancetta, Antonella Warnick, Eugene O’Connor, Robert Chen, Zhoumou Gizewski, Elizabeth Crane, Steven Gao, Zhan-Guo Auchampach, John A. Salvemini, Daniela Jacobson, Kenneth A. |
author_sort | Tosh, Dilip K. |
collection | PubMed |
description | [Image: see text] Purine (N)-methanocarba-5′-N-alkyluronamidoriboside A(3) adenosine receptor (A(3)AR) agonists lacking an exocyclic amine resulted from an unexpected reaction during a Sonogashira coupling and subsequent aminolysis. Because the initial C6-Me and C6-styryl derivatives had unexpectedly high A(3)AR affinity, other rigid nucleoside analogues lacking an exocyclic amine were prepared. Of these, the C6-Me-(2-phenylethynyl) and C2-(5-chlorothienylethynyl) analogues were particularly potent, with human A(3)AR K(i) values of 6 and 42 nM, respectively. Additionally, the C2-(5-chlorothienyl)-6-H analogue was potent and selective at A(3)AR (MRS7220, K(i) 60 nM) and also completely reversed mouse sciatic nerve mechanoallodynia (in vivo, 3 μmol/kg, po). The lack of a C6 H-bond donor while maintaining A(3)AR affinity and efficacy could be rationalized by homology modeling and docking of these hypermodified nucleosides. The modeling suggests that a suitable combination of stabilizing features can partially compensate for the lack of an exocyclic amine, an otherwise important contributor to recognition in the A(3)AR binding site. |
format | Online Article Text |
id | pubmed-4970510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-49705102017-02-18 Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists Tosh, Dilip K. Ciancetta, Antonella Warnick, Eugene O’Connor, Robert Chen, Zhoumou Gizewski, Elizabeth Crane, Steven Gao, Zhan-Guo Auchampach, John A. Salvemini, Daniela Jacobson, Kenneth A. J Med Chem [Image: see text] Purine (N)-methanocarba-5′-N-alkyluronamidoriboside A(3) adenosine receptor (A(3)AR) agonists lacking an exocyclic amine resulted from an unexpected reaction during a Sonogashira coupling and subsequent aminolysis. Because the initial C6-Me and C6-styryl derivatives had unexpectedly high A(3)AR affinity, other rigid nucleoside analogues lacking an exocyclic amine were prepared. Of these, the C6-Me-(2-phenylethynyl) and C2-(5-chlorothienylethynyl) analogues were particularly potent, with human A(3)AR K(i) values of 6 and 42 nM, respectively. Additionally, the C2-(5-chlorothienyl)-6-H analogue was potent and selective at A(3)AR (MRS7220, K(i) 60 nM) and also completely reversed mouse sciatic nerve mechanoallodynia (in vivo, 3 μmol/kg, po). The lack of a C6 H-bond donor while maintaining A(3)AR affinity and efficacy could be rationalized by homology modeling and docking of these hypermodified nucleosides. The modeling suggests that a suitable combination of stabilizing features can partially compensate for the lack of an exocyclic amine, an otherwise important contributor to recognition in the A(3)AR binding site. American Chemical Society 2016-02-18 2016-04-14 /pmc/articles/PMC4970510/ /pubmed/26890707 http://dx.doi.org/10.1021/acs.jmedchem.5b01998 Text en Copyright © 2016 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Tosh, Dilip K. Ciancetta, Antonella Warnick, Eugene O’Connor, Robert Chen, Zhoumou Gizewski, Elizabeth Crane, Steven Gao, Zhan-Guo Auchampach, John A. Salvemini, Daniela Jacobson, Kenneth A. Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists |
title | Purine (N)-Methanocarba Nucleoside
Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine
Receptor Agonists |
title_full | Purine (N)-Methanocarba Nucleoside
Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine
Receptor Agonists |
title_fullStr | Purine (N)-Methanocarba Nucleoside
Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine
Receptor Agonists |
title_full_unstemmed | Purine (N)-Methanocarba Nucleoside
Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine
Receptor Agonists |
title_short | Purine (N)-Methanocarba Nucleoside
Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine
Receptor Agonists |
title_sort | purine (n)-methanocarba nucleoside
derivatives lacking an exocyclic amine as selective a(3) adenosine
receptor agonists |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970510/ https://www.ncbi.nlm.nih.gov/pubmed/26890707 http://dx.doi.org/10.1021/acs.jmedchem.5b01998 |
work_keys_str_mv | AT toshdilipk purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT ciancettaantonella purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT warnickeugene purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT oconnorrobert purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT chenzhoumou purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT gizewskielizabeth purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT cranesteven purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT gaozhanguo purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT auchampachjohna purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT salveminidaniela purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists AT jacobsonkennetha purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists |